- Home
- TNON vs ONCO Comparison
TNON vs ONCO Comparison
Compare TNON & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | ONCO |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 2.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNON | ONCO |
|---|---|---|
| Price | $4.52 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 183.7K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | 22.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | $815,371.00 |
| Revenue This Year | $65.95 | N/A |
| Revenue Next Year | $50.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $0.13 | $0.09 |
| 52 Week High | $17.84 | $6.73 |
Technical Indicators
Market Signals| Indicator | TNON | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 36.66 |
| Support Level | $0.56 | $0.57 |
| Resistance Level | $7.15 | $1.01 |
| Average True Range (ATR) | 1.29 | 0.05 |
| MACD | -0.37 | -0.01 |
| Stochastic Oscillator | 0.86 | 15.94 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.